This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (38)  • Contact me when this article is cited  Related Content  • Related letter  • Similar articles in JAMA  Topic Collections  • HIV/AIDS  • Women's Health  • Pregnancy and Breast Feeding  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Howard Minkoff, MD; Mary Jo O'Sullivan, MD

JAMA. 1998;279:1743-1744.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

ZIDOVUDINE administration during pregnancy and the neonatal period reduces the rate of mother-to-child transmission of human immunodeficiency virus (HIV) type 1 by approximately two thirds. Analysis of data from the AIDS Clinical Trial Group (ACTG) 076 cohort^1-2 and subsequent reports^3-6 has revealed perinatal transmission rates in the 5% to 8% range in zidovudine-treated groups compared with previously reported rates of 20% or greater in untreated groups.^7-9 In late 1994, the Public Health Service developed recommendations for the use of zidovudine during the antepartum, intrapartum, and neonatal period,¹⁰ establishing the national standard of care for identified HIV-infected pregnant women.

The success of ACTG 076, while impressive, is not absolute; 2 challenges remain to optimize the prevention of mother-to-child transmission of HIV. First, steps must be taken to further drive the rate of transmission below the 8% level reported among the treated mothers in the . . . [Full Text of this Article]

From the Department of Obstetrics and Gynecology, Maimonides Medical Center, Brooklyn, NY (Dr Minkoff); State University of New York Health Science Center at Brooklyn (Dr Minkoff); and Jackson Memorial Hospital, University of Miami, Miami, Fla (Dr O'Sullivan).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Rapid HIV Screening During Labor
Kirsten Balano, Karen Beckerman, Valerie Ng, Howard Minkoff, and Mary Jo O'Sullivan
JAMA. 1998;280(19):1664.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Evaluation and Treatment of the Human Immunodeficiency Virus-1--Exposed Infant
King et al.
Pediatrics 2004;114:497-505.
ABSTRACT | FULL TEXT  

Rapid HIV-1 Testing During Labor: A Multicenter Study
Bulterys et al.
JAMA 2004;292:219-223.
ABSTRACT | FULL TEXT  

Policy Statements Adopted by the Governing Council of the American Public Health Association, October 24, 2001
AJPH 2002;92:451-483.
FULL TEXT  

Changing Epidemiology of Perinatal HIV-1 Infection in the United States
Shetty and Maldonado
NeoReviews 2001;2:e94-99.
FULL TEXT  

Technical Report: Perinatal Human Immunodeficiency Virus Testing and Prevention of Transmission
Mofenson and the Committee on Pediatric AIDS
Pediatrics 2000;106:88e-88.
ABSTRACT | FULL TEXT  

Prevention of Mother-to-Child HIV Transmission in Resource-Poor Countries: Translating Research Into Policy and Practice
De Cock et al.
JAMA 2000;283:1175-1182.
ABSTRACT | FULL TEXT  

Think HIV: Why Physicians Should Lower Their Threshold for HIV Testing
Freedberg and Samet
Arch Intern Med 1999;159:1994-2000.
FULL TEXT  

Can Perinatal HIV Infection Be Eliminated in the United States?
Mofenson
JAMA 1999;282:577-579.
FULL TEXT  

Rapid HIV Screening During Labor
Balano et al.
JAMA 1998;280:1664-1664.
FULL TEXT